Drug

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS "Non‑Degradative Molecular Glue" Inhibitor Advances into U.S. Clinical Trials
Betta PharmaceuticalsClinical trial approval / initiation

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS “Non‑Degradative Molecular Glue” Inhibitor Advances into U.S. Clinical Trials

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its wholly‑owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration…

Allist's Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

CancerClinical trial approval / initiation

CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor

Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis
Boehringer IngelheimProduct approvals

Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis

Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
BayerETR: BAYN

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Show More